Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
DRUGS FOR THE PREVENTION OF CORONARY-THROMBOSIS - FROM AN ANIMAL-MODEL TO CLINICAL-TRIALS
Autore:
FOLTS JD;
Indirizzi:
UNIV WISCONSIN,SCH MED,CTR CLIN SCI,DEPT MED,CARDIOL SECT,H6-379,600 HIGHLAND AVE MADISON WI 53792
Titolo Testata:
Cardiovascular drugs and therapy
, volume: 9, anno: 1995, supplemento:, 1
pagine: 31 - 43
SICI:
0920-3206(1995)9:<31:DFTPOC>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
CYCLIC FLOW VARIATIONS; ACUTE MYOCARDIAL-INFARCTION; PLATELET-ACTIVATING-FACTOR; UNSTABLE ANGINA; BLOOD-FLOW; RECEPTOR ANTAGONISTS; GLYCOPROTEIN-IIB/IIIA; SYNTHETASE INHIBITOR; ARTERIAL THROMBOSIS; MONOCLONAL-ANTIBODY;
Keywords:
ATHEROSCLEROTIC DISEASE; THROMBOTIC OCCLUSION; PLATELET AGGREGOMETRY; CYCLIC FLOW (FOLTS) MODEL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
103
Recensione:
Indirizzi per estratti:
Citazione:
J.D. Folts, "DRUGS FOR THE PREVENTION OF CORONARY-THROMBOSIS - FROM AN ANIMAL-MODEL TO CLINICAL-TRIALS", Cardiovascular drugs and therapy, 9, 1995, pp. 31-43

Abstract

Platelets contribute to the progression of atherosclerotic disease and also to partial or complete thrombotic occlusion of stenosed human coronary or cerebral arteries. Thus, there is considerable interest in being able to measure in vivo or ex vivo platelet function or level ofactivity. Currently, platelet activity and the platelet inhibitory effect of drugs can be assessed ex vivo or in vitro by platelet aggregometry. There is also an experimental animal model (the cyclic flow, or Felts, model) for studying the interactions of platelets with damaged and stenosed arterial walls. This model was first used to show that aspirin can prevent coronary thrombosis in stenosed canine coronary arteries and is fairly predictive in determining which drugs are likely toinhibit platelet activity in vivo. It is also useful in identifying which drugs may be beneficial in ameliorating unstable angina and preventing coronary thrombosis. Studies with this model predict that aspirin, sulfinpyrazone, the monoclonal antibody 7E3 to the platelet glycoprotein GpIIb-IIIa fibrinogen receptor, arginine-glycine-aspartic acid peptide mimetics, or clopidogrel (an analogue of ticlopidine) would inhibit platelet-mediated thrombosis in patients with coronary or cerebral artery stenosis. The model also predicts that heparin or dipyridamole alone would not prevent platelet-mediated arterial thrombosis. Finally, studies with the cyclic model suggest that while serotonin receptor blockers, alpha-adrenergic blockade, or infusions of prostacyclin (or its analogue, Iloprost) would inhibit platelet activity, the resulting hypotension would severely limit the clinical usefulness of these compounds.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 15:53:08